Plain-English translation of NCT06218303 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new vaccine called MUC1 vaccine (combined with an immune booster called Hiltonol) given alongside hormone therapy to see if it can help prevent early-stage breast cancer from developing into invasive disease. The study will look at how the vaccine affects your immune system and whether it reduces the chance of cancer recurrence. About 50 women with early-stage breast cancer (ductal carcinoma in situ) will participate.
Early-stage breast cancer detected by mammography doesn't always progress to invasive cancer, which means some patients receive more aggressive treatment than they need. This medication aims to help doctors use gentler treatment approaches by teaching your immune system to recognize and stop cancer cells before they become dangerous.
You likely qualify if…
You likely don't qualify if…
You would receive the vaccine as an injection under your skin, combined with hormone tablets you take by mouth daily (aromatase inhibitors or tamoxifen, depending on your menopausal status). The study will monitor your immune response through blood tests and tissue samples before and after treatment. You'll continue your planned breast surgery and hormone therapy as part of standard care while the research team tracks whether the vaccine helps prevent cancer recurrence.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States